Drug profile · INN
nadolol
CORGARD
nadolol (CORGARD) is a beta-1 adrenergic receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — nadolol
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
nadolol (CORGARD) is a beta-1 adrenergic receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Beta-1 adrenergic receptor antagonist
Primary target: Beta-1 adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is nadolol?
nadolol (CORGARD) is a beta-1 adrenergic receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for nadolol?
CORGARD is a marketed brand name for nadolol. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nadolol?
nadolol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.